| Tablet formulations involving alvelestat |
2023-12-22 |
2024-2-07 |
|
| Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
2023-4-07 |
2023-11-16 |
|
| Cancer biomarkers and cancer treatments |
2022-11-29 |
2023-8-10 |
|
| Methods for treating cancer |
2022-11-29 |
2023-8-10 |
|
| Vegf/dll4 binding agents and uses thereof |
2022-11-15 |
2023-9-07 |
|
| Neutrophil elastase inhibitors for use in the treatment of fibrosis |
2022-10-20 |
2023-7-01 |
|
| Methods of using anti-sclerostin antibodies in treatment of osteogenesis … |
2022-9-30 |
2023-6-16 |
|
| Methods for treatment of cancer comprising tigit-binding agents |
2022-6-28 |
2022-9-06 |
|
| Treatment of proteinase 3 mediated disease |
2022-3-07 |
2022-4-20 |
|
| Alvelestat for use in the treatment of graft rejection, bronchiolitis … |
2022-2-28 |
2022-5-01 |
|
| TIGIT COMMITMENT FACTORS AND THEIR USES |
2021-12-17 |
2023-3-24 |
|
| Combination therapy for treatment of disease |
2021-5-26 |
2021-12-30 |
|
| Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol … |
2021-3-18 |
2021-5-31 |
|
| Synthetic method for the preparation of an alkoxymethylene-benzoylacetonitrile |
2021-3-18 |
2021-5-31 |
|
| Synthetic method for the preparation of an hydrazine compound |
2021-3-18 |
2021-5-31 |
|
| Methods involving neutrophil elastase inhibitor alvelestat for treating … |
2021-3-16 |
2022-10-13 |
|
| Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
2021-2-26 |
2021-8-19 |
|
| Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)- … |
2021-1-14 |
2022-9-06 |
2022-9-06 |
| Elastase inhibition |
2020-4-16 |
2020-6-03 |
|
| Elastase inhibition |
2020-4-16 |
2020-6-03 |
|
| Dosage regimen for the treatment of acute exacerbations of chronic obstructive … |
2020-2-18 |
2020-9-10 |
|
| Use of a sclerostin antagonist |
2019-6-28 |
2020-1-02 |
|
| Elastate inhibition |
2019-4-16 |
2019-5-29 |
|
| Elastase inhibition |
2019-4-16 |
2019-5-29 |
|
| Hypogonadism and related diseases |
2019-3-20 |
2019-5-01 |
|
| Hypogonadism and related diseases |
2019-3-20 |
2019-5-01 |
|
| Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)- … |
2018-12-23 |
2022-4-01 |
|
| Use of 3- [5-amino-4- (3-cyanobenzoyl) -pyrazol-1-yl] -N-cyclopropyl-4- … |
2018-12-11 |
2021-12-03 |
2021-12-03 |
| Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4- … |
2018-12-11 |
2020-8-18 |
|
| Eastase inhibitor |
2018-6-18 |
2018-8-01 |
|
| Elastase Inhibition |
2018-6-18 |
2018-8-01 |
|
| Therapeutic combination and methods of treatment with a DLL4 antagonist and an … |
2018-4-30 |
2020-12-22 |
2020-12-22 |
| Hypogonadism and related diseases |
2018-3-19 |
2018-5-02 |
|
| Hypogonadism and related diseases |
2018-3-19 |
2018-5-02 |
|
| Treatment of chronic obstructive pulmonary disease |
2018-2-13 |
2018-3-28 |
|
| Treatment of chronic obstructive pulmonary disease |
2018-2-13 |
2018-3-28 |
|
| Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4- … |
2017-12-11 |
2018-1-24 |
|
| Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4- … |
2017-12-11 |
2018-1-24 |
|
| Dosage regimen for the treatment of endometriosis |
2017-8-21 |
2019-6-26 |
|
| Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)- … |
2017-7-13 |
2024-2-20 |
2024-2-20 |
| COMPOSITIONS AND METHODS OF USE FOR STRENGTHENING ANTIBODIES |
2017-3-06 |
2017-7-12 |
|
| USE OF A FLAVORING INHIBITOR FOR HYPOTHESIS AND RELATED DISEASES |
2017-1-24 |
2017-7-12 |
|
| USE OF A BYU PRODUCTION IN TREATMENT OF ACUTE EXTREMES OF COLD TEMPERATURE |
2016-11-18 |
2017-6-28 |
|
| Methods and compositions for treatment of cancer |
2016-9-23 |
2019-6-19 |
|
| Methods and monitoring of treatment with a WNT pathway inhibitor |
2016-5-05 |
2018-6-05 |
2018-6-05 |
| Dosage regimen for the treatment of acute exacerbations of inflammatory … |
2016-3-08 |
2020-4-14 |
2020-4-14 |
| Method for Making Heteromultimeric Molecules |
2016-3-03 |
2016-9-29 |
|
| Dosage regimen for the treatment of acute exacerbations of inflammatory … |
2016-2-08 |
2016-3-23 |
|
| Dosage regimen for the treatment of acute exacerbations of inflammatory … |
2016-2-08 |
2016-3-23 |
|
| Compositions and Methods for Diagnosing and Treating Cancer |
2015-11-30 |
2016-6-30 |
|
| RSPO3 binding agents and uses thereof |
2015-9-30 |
2017-3-21 |
2017-3-21 |
| Treatment of Fibrotic Diseases |
2015-9-15 |
2016-6-16 |
|
| Wnt antagonist and methods of treatment and screening |
2015-9-01 |
2017-2-28 |
2017-2-28 |
| Compositions and methods for treating and diagnosing cancer |
2015-4-22 |
2015-11-26 |
|
| Method of treating cancer by administering a monoclonal antibody that binds … |
2015-1-20 |
2016-11-29 |
2016-11-29 |
| Compositions and methods for diagnosing and treating cancer |
2014-6-18 |
2016-2-25 |
|
| Methods and Monitoring of Treatment with a DLL4 Antagonist |
2013-10-31 |
2014-8-07 |
|
| Methods for treating melanoma |
2013-9-06 |
2016-11-01 |
2016-11-01 |
| Frizzled-binding agents and uses thereof |
2013-8-23 |
2016-11-22 |
2016-11-22 |
| Compositions and methods for diagnosing and treating cancer |
2013-3-14 |
2016-1-05 |
2016-1-05 |
| Monoclonal antibodies against frizzled |
2013-3-13 |
2016-3-01 |
2016-3-01 |
| 5-membered heterocycle-based p38 kinase inhibitors |
2013-2-25 |
2013-7-04 |
|
| Use of an aromatase inhibitor for the treatment of hypogonadism and related … |
2012-9-06 |
2016-5-27 |
|
| Compositions and methods for diagnosing and treating cancer |
2006-10-31 |
2017-12-26 |
2017-12-26 |
| Procede de production d'une forme polymorphe de 3- [5-amino-4-(3-cyanobenzoyl)- … |
2017-7-13 |
2024-2-20 |
2024-2-20 |